MX2019006189A - Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea. - Google Patents

Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea.

Info

Publication number
MX2019006189A
MX2019006189A MX2019006189A MX2019006189A MX2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A MX 2019006189 A MX2019006189 A MX 2019006189A
Authority
MX
Mexico
Prior art keywords
peptide
drug
hormone receptor
parathyroid hormone
targeting
Prior art date
Application number
MX2019006189A
Other languages
English (en)
Inventor
S Low Philip
A Low Stewart
Jay Howard Nielsen Jeffery
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of MX2019006189A publication Critical patent/MX2019006189A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un sistema de suministro de fármaco que comprende al menos un péptido y un ligando dirigido para fractura ósea y/o para curación ósea. Algunas modalidades incluyen un sistema de suministro de péptido que comprende al menos un péptido acídico, básico, hidrofílico, hidrofóbico o neutral, ligado a un péptido acídico o polianión no peptídico para uso en dirigir el péptido unido mencionado antes a la superficie de una fractura ósea. En algunas modalidades, un péptido conjugado expresa una función anabólica que actúa a través del receptor 1 de la PTH, y varios formatos de ligandos dirigidos guían el fármaco a hidroxiapatito puro. Este sistema compensa algunos efectos secundarios causados por el fármaco anabólico libre, tal como alta concentración de calcio en sangre.
MX2019006189A 2016-11-30 2017-11-30 Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea. MX2019006189A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428492P 2016-11-30 2016-11-30
US201762553313P 2017-09-01 2017-09-01
PCT/US2017/064081 WO2018102616A1 (en) 2016-11-30 2017-11-30 Fracture targeted bone regeneration through parathyroid hormone receptor stimulation

Publications (1)

Publication Number Publication Date
MX2019006189A true MX2019006189A (es) 2019-11-18

Family

ID=62241919

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006189A MX2019006189A (es) 2016-11-30 2017-11-30 Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea.

Country Status (10)

Country Link
US (3) US20200317745A1 (es)
EP (1) EP3548012A4 (es)
JP (2) JP2020500871A (es)
CN (1) CN110114065A (es)
AU (1) AU2017367699B2 (es)
BR (1) BR112019011070A2 (es)
CA (1) CA3045458A1 (es)
IL (1) IL266977B2 (es)
MX (1) MX2019006189A (es)
WO (1) WO2018102616A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266977B2 (en) * 2016-11-30 2024-01-01 Purdue Research Foundation Fracture-targeted bone regeneration using thyroid hormone receptor stimulation
WO2019232285A1 (en) * 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
CN110551201B (zh) * 2019-08-26 2020-04-28 杭州彗搏科技有限公司 一种新型骨形成蛋白2来源的环肽、制备方法及其应用
CN112646042A (zh) * 2019-10-10 2021-04-13 陕西麦科奥特科技有限公司 活性多肽化合物
WO2022093374A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat spinal fusions
JP2024506435A (ja) * 2020-10-26 2024-02-14 パーデュー リサーチ ファウンデーション 化合物、組成物、および骨折を処置するための使用方法
WO2023136866A1 (en) * 2022-01-14 2023-07-20 Novosteo Llc Bone targeted treatment in osteogenesis imperfecta

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2098283A1 (en) * 1990-12-21 1992-06-22 Richard P. Bozzato Oxidation resistant variants of parathyroid hormone
WO1995002610A1 (en) * 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
EP1062229A1 (en) * 1998-03-09 2000-12-27 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US7057012B1 (en) * 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
JP2000327583A (ja) * 1999-05-17 2000-11-28 Medei Sci Puraningu:Kk 骨指向性ホルモン誘導体
WO2004062588A2 (en) * 2003-01-06 2004-07-29 University Of Utah Water-soluble polymeric bone-targeting drug delivery system
JP4874954B2 (ja) * 2004-04-21 2012-02-15 エノビア ファーマ インコーポレイティド 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法
US7863238B2 (en) * 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
PT2957278T (pt) * 2006-10-03 2017-08-23 Ipsen Pharma Sas Uma composição estável compreendendo pthrp e utilizações da mesma
JP5520811B2 (ja) * 2007-04-09 2014-06-11 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合領域と副甲状腺ホルモンとの融合タンパク
DK2158319T3 (da) * 2007-05-11 2012-03-19 Enobia Pharma Inc Knoglemålrettet alkalisk fosfatase, kits og fremgangsmåder til anvendelse deraf
WO2009141823A2 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
EP3332799A1 (en) * 2011-04-22 2018-06-13 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
CN102824647B (zh) * 2011-06-13 2014-07-23 香港中文大学 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法
US9718868B2 (en) * 2012-08-28 2017-08-01 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof
EP3016674A4 (en) * 2013-06-23 2017-03-15 Wisconsin Alumni Research Foundation Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same
ES2927067T3 (es) * 2015-03-03 2022-11-02 Radius Health Inc Abaloparatida combinada con alendronato para la reducción de las fracturas óseas no vertebrales
WO2016196400A1 (en) * 2015-05-29 2016-12-08 Purdue Research Foundation Bone fracture repair by targeting of agents that promote bone healing
CN106039316B (zh) * 2016-05-03 2019-04-02 同济大学 一种基于多肽构建的成骨细胞靶向载体及其制备与应用
IL266977B2 (en) * 2016-11-30 2024-01-01 Purdue Research Foundation Fracture-targeted bone regeneration using thyroid hormone receptor stimulation
JP2024506435A (ja) * 2020-10-26 2024-02-14 パーデュー リサーチ ファウンデーション 化合物、組成物、および骨折を処置するための使用方法

Also Published As

Publication number Publication date
EP3548012A4 (en) 2020-07-22
RU2019119701A3 (es) 2021-02-16
RU2019119701A (ru) 2021-01-14
JP2020500871A (ja) 2020-01-16
AU2017367699A1 (en) 2019-07-11
BR112019011070A2 (pt) 2019-10-01
CA3045458A1 (en) 2018-06-07
US20200317745A1 (en) 2020-10-08
IL266977B2 (en) 2024-01-01
AU2017367699A8 (en) 2019-07-25
US20200316174A1 (en) 2020-10-08
EP3548012A1 (en) 2019-10-09
CN110114065A (zh) 2019-08-09
WO2018102616A1 (en) 2018-06-07
IL266977A (en) 2019-07-31
AU2017367699B2 (en) 2023-12-07
US10960054B2 (en) 2021-03-30
US20210283227A1 (en) 2021-09-16
IL266977B1 (en) 2023-09-01
JP2023029957A (ja) 2023-03-07

Similar Documents

Publication Publication Date Title
MX2019006189A (es) Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
SG11201810939PA (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
IN2015DN03219A (es)
PH12016500433A1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
WO2014052935A3 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2018014279A (es) Tratamiento terapeutico de cancer de mama con base en estado de c-maf.
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
MX2020011333A (es) Uso terapeutico de proteinas morfogeneticas oseas.
MX2019014483A (es) Regimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para el tratamiento de endometriosis.
MX2019013857A (es) Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico.
EA201691567A1 (ru) Способы лечения легких травм головного мозга
CN106572870A8 (zh) 柔性上下颌骨固定装置
MX2017016418A (es) Composiciones de liraglutida de acción prolongada.
NZ721835A (en) An osseointegrable device
BR112014021497A2 (pt) sistema de entrega de fármaco baseado em jcv-vlp
MX2018004041A (es) Tratamiento de trastornos de acidos biliares.
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
BR112017002878A2 (pt) distribuição coordenada de tratamento de copd
EP3626712A3 (en) Liver x receptor (lxr) modulators
BR112019024875A2 (pt) Métodos para o tratamento da ileíte do reservatório crônica
WO2016026917A3 (en) Medicament and apparatus for treating chronic kidney disease
Avci Ibandronic acid
PH12018502195A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases